FIBROGEN INC - COMMON STOCK

0.2639

13-June-25 13:45:00

15 minutes delayed

Stocks

-0.0446

-14.46%

Today's range

0.2423 - 0.2885

ISIN

N/A

Source

NASDAQ

FibroGen Receives Rare Pediatric Disease Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

15 Apr 2021 04:00:00 By Nasdaq GlobeNewswire
FibroGen Receives Fast Track Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

12 Apr 2021 04:00:01 By Nasdaq GlobeNewswire
FibroGen Announces FDA Advisory Committee to Review Roxadustat New Drug Application Tentatively Scheduled for July 15, 2021

06 Apr 2021 16:50:31 By Nasdaq GlobeNewswire
FibroGen Provides Additional Information on Roxadustat

06 Apr 2021 13:01:00 By Nasdaq GlobeNewswire
FibroGen Initiates LELANTOS-2 – Second Phase 3 Clinical Study of Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

16 Mar 2021 04:00:00 By Nasdaq GlobeNewswire
FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results

01 Mar 2021 13:01:00 By Nasdaq GlobeNewswire
FibroGen Provides Regulatory Update on Roxadustat

01 Mar 2021 13:01:00 By Nasdaq GlobeNewswire
FibroGen to Report Fourth Quarter and Full Year 2020 Financial Results

18 Feb 2021 04:00:01 By Nasdaq GlobeNewswire
FibroGen to Present at Upcoming Investor Conferences

12 Feb 2021 04:00:00 By Nasdaq GlobeNewswire

<<
<
2
3
4
5
6
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.